RedHill Biopharma Ltd.

Overview

Overview

RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal and infectious diseases, with emerging programs in oncology and central nervous system (CNS) disorders. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill has established itself as a specialty pharma company with a diverse pipeline targeting unmet medical needs in GI, infectious diseases, and increasingly, neurodegenerative conditions["@redhill"].

The company trades on the NASDAQ under the ticker RDHL and has built its portfolio through a combination of in-house development and strategic acquisitions of late-stage clinical candidates. While RedHill's primary focus has been on gastrointestinal and infectious diseases, the company has progressively expanded its strategic interests to include CNS disorders, particularly those with gastrointestinal components such as Parkinson's disease["@sec"].

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Tel Aviv, Israel |
| Founded | 2009 |
| Ticker | NASDAQ: RDHL |
| Focus Areas | GI diseases, Infectious diseases, Oncology, CNS |
| Status | Public (clinical-stage) |
| Employees | ~50-100 |

History and Development

RedHill Biopharma was founded in 2009 with a strategic focus on late-stage clinical development of novel therapeutic candidates. The company's business model emphasizes:

Key Milestones

• 2009: Company founded in Israel
• 2013: Movantik (naloxegol) licensing agreement with AstraZeneca
• 2014: Initial public offering on NASDAQ
• 2018: Talicia (RHB-105) FDA approval for H. pylori
• 2018: Aemcolo (RHB-412) FDA approval for travelers' diarrhea
• 2019: Expansion of CNS programs and research initiatives
• 2020-2024: Continued pipeline advancement including upamostat and RHB-107

Technology Platform and Research Approach

RedHill's research approach combines expertise in several therapeutic areas:

Gastrointestinal Expertise

The company's foundation in GI drugs provides unique insights into conditions with gut-brain axis involvement:

CNS Research Interests

RedHill's expansion into CNS has focused on conditions with established or hypothesized gut connections:

Pipeline and Programs

Approved Products

Movantik/Naloxegol

Movantik (naloxegol) is a peripheral μ-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC)[@movantik].

• Mechanism: Selective antagonist of peripheral μ-opioid receptors in the GI tract, blocking opioid-induced inhibition of intestinal motility without affecting central opioid analgesia
• Indication: Opioid-induced constipation in adults with chronic non-cancer pain
• Status: FDA approved (2014), marketed globally
• Partnership: Licensed to AstraZeneca for global commercialization

Talicia

Talicia (RHB-105) is a fixed-dose combination therapy for the treatment of Helicobacter pylori infection[@talicia].

• Mechanism: Triple-combination therapy including amoxicillin, clarithromycin, and omeprazole
• Indication: Helicobacter pylori infection
• Status: FDA approved (2018) — First approval for a RedHill-developed drug
• Significance: Demonstrated company's ability to advance drugs through regulatory approval

Aemcolo

Aemcolo (RHB-412/rifamycin MMX) is a rifamycin-based antibiotic for the treatment of travelers' diarrhea[@aemcolo].

• Mechanism: Broad-spectrum antibiotic with MMX colonic delivery technology
• Indication: Travelers' diarrhea caused by non-invasive strains of E. coli
• Status: FDA approved (2018)

Clinical Pipeline

RHB-107 (Upamostat)

RHB-107 (upamostat) is a serine protease inhibitor with potential applications in oncology and virology.

• Mechanism: Inhibits serine proteases involved in tumor invasion and viral entry
• Indication: Various cancers, potential for viral infections
• Stage: Phase 2 clinical trials
• CNS Potential: Research has explored CNS applications given protease involvement in neuroinflammation

RHB-104

RHB-104 is an oral combination therapy for Mycobacterium avium complex (MAC) infection.

• Mechanism: Combination antibiotic regimen
• Indication: MAC infection, a common opportunistic infection in immunocompromised patients
• Stage: Phase 3 clinical trials
• Neurodegeneration Link: Research has explored connections between mycobacterial infections and neuroinflammation

CNS Pipeline Evolution

RedHill has progressively expanded its CNS interest, particularly in neurodegenerative diseases:

| Program | Stage | Indication | Neurodegeneration Relevance |
|---------|-------|------------|----------------------------|
| RHB-107 (upamostat) | Phase 2 | Various cancers | Protease inhibition in neuroinflammation |
| RHB-104 | Phase 3 | MAC infection | Microbial-neuroinflammation connections |
| CNS-001 | Discovery | Neurodegeneration | Gut-brain axis modulators |

Parkinson's Disease Relevance

RedHill's expertise in gastrointestinal therapeutics positions them uniquely for Parkinson's disease research, given the strong gut-brain axis connections documented in PD pathophysiology[@gutbrainpd][@microbiomepd].

α-Synuclein and the Gut

Research has established compelling connections between gut health and Parkinson's disease:

Microbiome Alterations

PD patients demonstrate distinct microbiome profiles compared to healthy controls[@microbiomepd]:

• Reduced microbial diversity
• Increased pro-inflammatory bacteria
• Decreased anti-inflammatory species
• Metabolite alterations (short-chain fatty acids, etc.)

Opioid Signaling in PD

Parkinson's disease patients often develop constipation from dopaminergic medications, and opioid signaling is altered in PD:

• Movantik (naloxegol): As a peripheral μ-opioid receptor antagonist, may have utility in PD-associated constipation management
• Opioid Dysregulation: Research has documented altered opioid peptide levels in PD brains
• Pain Management: PD patients often require pain management where opioid antagonists may play a role

Clinical Trial Considerations

PD clinical trials require specific considerations:

| Factor | Relevance | RedHill Capability |
|--------|-----------|-------------------|
| Motor symptoms | UPDRS, MDS-UPDRS, Hoehn & Yahr staging | Clinical trial infrastructure |
| Non-motor symptoms | REM sleep behavior disorder, constipation, depression | GI expertise relevant |
| Biomarkers | α-synuclein PET ligands, DaTscan imaging | Biomarker development capability |
| Disease stage | Early vs. advanced PD | Patient stratification understanding |
| GI complications | Constipation, microbiome | Direct therapeutic relevance |

Alzheimer's Disease Potential

While RedHill's CNS expansion has focused primarily on PD, the company's approach has implications for AD:

Neuroinflammation

Both GI and CNS inflammation share common pathways:

• IL-6 and TNF-α: Pro-inflammatory cytokines elevated in both GI inflammation and AD
• Microglial Activation: Common pathway in neuroinflammation and GI inflammation
• Peripheral-CNS Communication: Inflammatory signals from gut may influence brain inflammation

Blood-Brain Barrier

Strategies for GI drug delivery may inform CNS delivery:

• Barrier Modulation: Understanding of epithelial barriers may translate to BBB strategies
• Transporter Exploitation: Carrier-mediated transport for GI drugs may have CNS analogs
• Nanoparticle Delivery: Experience with GI nanoparticles may inform brain delivery

Competitive Landscape

RedHill operates in a competitive landscape across multiple therapeutic areas:

GI Competition

| Company | Key Products | RedHill Differentiation |
|---------|-------------|------------------------|
| AstraZeneca | Movantik (licensed) | Co-development partner |
| Ferring | Picoprep | Different mechanism |
| Salix | Xifaxan | Similar MMX technology |

Neurodegeneration Competition

| Company | Approach | RedHill Advantage |
|---------|----------|-------------------|
| Biogen/Eisai | Anti-amyloid antibodies | Gut-brain axis expertise |
| Roche | Anti-tau antibodies | Different mechanism |
| Generic dopaminergic | Symptomatic treatment | Novel mechanisms |

Financial Overview

RedHill's financial position reflects its clinical-stage status[@sec]:

• Market Capitalization: $50-150M range (variable based on pipeline news)
• Revenue: Product sales from Movantik, Talicia, and Aemcolo
• Partnerships: Strategic collaborations with AstraZeneca and others
• R&D Investment: Significant investment in clinical development

Strategic Positioning

RedHill's strategic approach to neurodegeneration leverages several key assets:

Strengths

Opportunities

Challenges

Research and Development Strategy

RedHill's approach to neurodegeneration R&D includes:

Short-Term (1-2 years)

• In-licensing: Acquire CNS candidates with established proof-of-concept
• Academic Partnerships: Collaborate with PD researchers on gut-brain axis
• Biomarker Development: Validate biomarkers linking GI and CNS endpoints

Medium-Term (2-5 years)

• Clinical Trials: Initiate PD-focused clinical trials
• Indication Expansion: Explore AD and other neurodegenerative conditions
• Combination Therapies: Develop GI + CNS combination approaches

Long-Term (5+ years)

• Platform Development: Build proprietary neurodegeneration platform
• Global Launch: Commercialize neurodegeneration products
• Pipeline Expansion: Diversify CNS pipeline

Collaboration Opportunities

RedHill may pursue various collaboration models:

Future Directions

The company's expansion into CNS reflects broader industry recognition of gut-brain connections in neurodegeneration:

• Phase 2initiation: RHB-107 CNS-focused trials
• Pipeline Additions: Acquire additional CNS candidates
• PD Program: Initiate dedicated Parkinson's disease program
• Biomarker Development: Validate predictive biomarkers

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Gut-Brain Axis in Parkinson's Disease](/mechanisms/gut-brain-axis-parkinsons)
• [Opioid Signaling in Neurodegeneration](/mechanisms/opioid-signaling-neurodegeneration)
• [Microbiome and Neurodegeneration](/mechanisms/microbiome-neurodegeneration)
• [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)

External Links

• [RedHill Biopharma Official Website](https://www.redhillbio.com)
• [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001554463)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

References